# Senti Biosciences Holdings, Inc.: overview SNTI · Nasdaq · CIK 1854270 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/snti.md) · [Financials](/companies/snti/financials.md) · [Filings](/companies/snti/filings.md) · [Insiders](/companies/snti/insiders.md) Latest reported revenue: [$17.0k](/filings/0001628280-26-057110.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001628280-26-057110). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [0.0](/filings/0001854270-24-000116.md) | [0.0 d](/filings/0001628280-26-021580.md) | [0.0](/filings/0001628280-26-035126.md) | [0.0](/filings/0001628280-26-057110.md) | not reported | not reported | [0.0](/filings/0001628280-26-035126.md) | [0.0](/filings/0001628280-26-057110.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(28850.0%)](/filings/0001628280-26-035126.md) | [(85229.4%)](/filings/0001628280-26-057110.md) | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | [(26381.3%)](/filings/0001628280-26-057110.md) | [(75000.0%)](/filings/0001628280-26-057110.md) | | Diluted EPS | $ per share | [(6.31)](/filings/0001628280-25-052125.md) | not reported | [(1.41)](/filings/0001628280-26-035126.md) | [(0.56)](/filings/0001628280-26-057110.md) | [(0.69)](/filings/0001628280-25-052125.md) | not reported | [(0.14)](/filings/0001628280-26-035126.md) | [(0.41)](/filings/0001628280-26-057110.md) | | Free cash flow | $m | [(7.9) d](/filings/0001628280-25-052125.md) | [(13.5) d](/filings/0001628280-26-021580.md) | [(14.1)](/filings/0001628280-26-035126.md) | [(13.3) d](/filings/0001628280-26-057110.md) | [(9.4) d](/filings/0001628280-25-052125.md) | [(6.9) d](/filings/0001628280-26-021580.md) | not reported | not reported | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [2.3](/filings/0001854270-23-000033.md) | [3.3](/filings/0001854270-24-000029.md) | [2.0](/filings/0001854270-25-000042.md) | [0.0](/filings/0001628280-26-021580.md) | [0.0](/filings/0001628280-26-021580.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(1765.4%)](/filings/0001854270-23-000033.md) | [(1889.3%)](/filings/0001854270-24-000029.md) | [(4687.9%)](/filings/0001854270-25-000042.md) | not reported | [(312631.8%)](/filings/0001628280-26-021580.md) | | Net margin | % | [(2414.6%)](/filings/0001854270-23-000033.md) | [(1771.5%)](/filings/0001854270-24-000029.md) | [(3592.4%)](/filings/0001854270-25-000042.md) | not reported | [(279263.6%)](/filings/0001628280-26-021580.md) | | Diluted EPS | $ per share | [(19.00)](/filings/0001854270-23-000033.md) | [(2.23)](/filings/0001854270-24-000029.md) | [(16.01)](/filings/0001854270-25-000042.md) | [(12.03)](/filings/0001628280-26-021580.md) | [(2.73)](/filings/0001628280-26-021580.md) | | Free cash flow | $m | [(40.2)](/filings/0001854270-23-000033.md) | [(76.3)](/filings/0001854270-24-000029.md) | [(64.4)](/filings/0001854270-25-000042.md) | [(41.4)](/filings/0001628280-26-021580.md) | [(43.6)](/filings/0001628280-26-021580.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/snti/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Nantahala Capital Management, LLC](/funds/1472322.md) | 2026-06-30 | $976.8k | 888,000 | | New +888,000 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $591.3k | 537,504 | | New +537,504 | | [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $205.8k | 187,065 | | New +187,065 | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $117.8k | 107,100 | | New +107,100 | | [VANGUARD FIDUCIARY TRUST CO](/funds/933478.md) | 2026-06-30 | $100.3k | 91,193 | | New +91,193 | | [JANE STREET GROUP, LLC](/funds/1595888.md) | 2026-06-30 | $57.8k | 52,530 | | New +52,530 | | [Menlo Ventures Management, L.P.](/funds/1911541.md) | 2026-06-30 | $39.3k | 35,737 | | New +35,737 | | [NORTHERN TRUST CORP](/funds/73124.md) | 2026-06-30 | $35.4k | 32,154 | | New +32,154 | | [XTX Topco Ltd](/funds/1828301.md) | 2026-06-30 | $26.0k | 23,610 | | New +23,610 | | [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $15.9k | 14,432 | | New +14,432 | ## Recent filings [All 361 filings](/companies/snti/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 16:17 ET | [8-K](/filings/0001140361-26-040772.md) | 1.01 Entry into a material agreement; 1.02 Termination of a material agreement; 2.01 Completion of an acquisition or disposition; 3.02 Unregistered sale of equity; 9.01 Financial statements and exhibits | 0001140361-26-040772 | | 2026-10-15 | 16:02 ET | [8-K](/filings/0001628280-26-065992.md) | 5.07 Shareholder vote results | 0001628280-26-065992 | | 2026-10-13 | 16:01 ET | [8-K](/filings/0001628280-26-065685.md) | 8.01 Other events | 0001628280-26-065685 | | 2026-09-24 | 16:03 ET | [8-K](/filings/0001628280-26-063369.md) | 5.02 Departure or appointment of officers or directors | 0001628280-26-063369 | | 2026-09-11 | 17:00 ET | [SCHEDULE 13D/A](/filings/0000902664-26-003795.md) | Ownership report, active investor, amended | 0000902664-26-003795 | | 2026-09-04 | 06:01 ET | [8-K](/filings/0001628280-26-060600.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation; 9.01 Financial statements and exhibits | 0001628280-26-060600 | | 2026-09-02 | 16:29 ET | [8-K](/filings/0001628280-26-060124.md) | 1.01 Entry into a material agreement; 3.01 Delisting notice | 0001628280-26-060124 | | 2026-08-20 | 16:25 ET | [8-K](/filings/0001628280-26-058258.md) | 1.01 Entry into a material agreement; 2.03 New direct financial obligation | 0001628280-26-058258 | | 2026-08-14 | 16:10 ET | [10-Q](/filings/0001628280-26-057110.md) | Quarterly report, period 2026-06-30 | 0001628280-26-057110 | | 2026-07-16 | 13:56 ET | [SCHEDULE 13D/A](/filings/0000902664-26-003126.md) | Ownership report, active investor, amended | 0000902664-26-003126 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001628280-26-021580.md), filed Mar 27, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/824d003e-7c91-4ebf-a16b-4c3ff1014484) ## About the filer - CIK: 1854270 - Tickers: SNTI - Exchange: Nasdaq - SIC code: 2836 Biological Products, (No Diagnostic Substances) - State of incorporation: DE - Filer category:
Emerging growth company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 27, 2026, 16:38 ET. No prices; not investment advice.